Issue of Equity

Futura Medical PLC
15 November 2007


For immediate release                                         15 November 2007





                               Futura Medical Plc
                   Agrees £2 million equity funding facility



Futura Medical plc (AIM: FUM), the pharmaceutical and medical device group, is
pleased to announce that it has agreed a £2 million (gross) funding facility
under which an initial £1 million (net) is being raised through the issue of
2,059,308 new ordinary shares of 0.2p each in the Company at a price of 48.56p
per share.

Under the terms of the funding facility, the Company will have the ability to
raise up to a further £1.0 million (net) through the issue of new ordinary
shares at a price per share at a 10 per cent discount to the average mid-price
of the Company's shares during the five trading days prior to the agreement to
issue the second tranche of shares. The 5% cost of the arrangement of the
funding facility has been satisfied by the issue of 205,931 new ordinary shares
of 0.2p each in the Company at a price of 48.56p per share.

The new ordinary shares will rank pari passu with the existing ordinary shares
of 0.2p each in the Company. Application has been made to AIM and it is
anticipated that trading of the new ordinary shares on AIM will commence on 20
November 2007. The Company's total issued share capital following the
anticipated admission of the shares as set out above is 57,618,840.

The funds raised from this funding facility are for general corporate purposes,
including the support of the ongoing development of products within Futura's
existing pipeline. The funds will also allow initial development of selected new
opportunities generated by the Company's R&D initiatives.


Commenting on the results James Barder, Futura's Chief Executive, said: 'I am
delighted by the support from both new and existing shareholders for this
funding facility, which provides additional funds to maintain the momentum of
product development at Futura. We are particularly pleased by the number of
opportunities being generated by our in-house R&D at a time when our most
advanced product moves close to commercial launch.'





For further information:
 Futura Medical plc                                  Tel: [phone]
 James Barder, Chief Executive 
 email to: [e-mail]          www.futuramedical.co.uk


Canaccord Adams                                      Tel: [phone]
 Mark Ashurst


Media enquiries:
 Buchanan Communications                             Tel: [phone]
 Mark Court / Rebecca Skye Dietrich







Notes

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for
consumer healthcare.  The Company is developing a portfolio of products and its
strategy is to license their manufacture and distribution to major
pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.

www.futuramedical.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange